Neumora Therapeutics, Inc.
NMRA evidence brief
What we can confirm
- BioSniper Score:
- 6.5 / 10
- Market Cap:
- $214.2M
- Lead Asset:
- navacaprant (Phase 3)
What it means
What to watch
Prepared research question
What matters most for NMRA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NMRA
Neumora Therapeutics (NMRA) is a clinical-stage biopharmaceutical company developing a pipeline of novel CNS and metabolic disease programs, with a focus on precision neuroscience and mechanisms such as NLRP3 inhibition, M4 PAM, and V1aR antagonism.
Key risk: No approved products
BioSniper Score
Based on 4 of 6 signals
Market Cap
$214.2M
Cash Runway
—
Lead Asset
navacaprant (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 7 pipeline candidates · 7 clinical trials for Neumora Therapeutics, Inc..
Neumora Therapeutics (NMRA) is a clinical-stage biopharmaceutical company developing a pipeline of novel CNS and metabolic disease programs, with a focus on precision neuroscience and mechanisms such as NLRP3 inhibition, M4 PAM, and V1aR antagonism.
- Cash & equivalents of $116.8M as of 2026-06-30 [sec].
- Net income of -$43.1M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $44.5M as of 2026-06-30 [sec].
- Pipeline includes NMRA-215 (NLRP3 inhibitor for obesity), NMRA-898 (M4 PAM for schizophrenia), and NMRA-511 (V1aR antagonist for Alzheimer's agitation) [sec_mda · as of 2026-03-30].
- Cash runway expected into the third quarter of 2027 following a reduction in force [sec · filed 2026-06-15].
What works
- Multiple pipeline programs targeting novel mechanisms (NLRP3, M4 PAM, V1aR) with upcoming clinical data catalysts in 2026 [sec_mda · as of 2026-03-30].
- Cash runway into Q3 2027 provides a multi-year operational buffer for ongoing development [sec · filed 2026-06-15].
- Favorable preclinical toxicology results for NMRA-215 support planned IND submission in Q4 2026 [news · published 2026-07-27].
What to weigh
- Net loss of $43.1M in the latest reported period (as of 2026-06-30) with no approved products generating revenue [sec].
- Shareholders' equity of only $44.5M against cash of $116.8M, indicating significant accumulated deficits and limited financial cushion beyond cash runway [sec].
- Reliance on forward-looking statements and inherent clinical trial risks, with comparisons to other sponsors' efficacy results cautioned as uncertain [sec · filed 2026-06-15].
- Reduction in force suggests cost‑cutting measures, which may impact development capacity [sec · filed 2026-06-15].
From the filings
Quoted directly from source documents.
Cash runway into Q3 2027
“the Company expects its current cash and cash equivalents to provide runway into the third quarter of 2027.”
SEC filings · June 15, 2026
NMRA-215 IND plan
“plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026”
News · August 14, 2026
Risks & what to watch (3)›
Key risks
- No approved products — Company has no marketed drugs; all revenue is zero and relies solely on pipeline success [sec].
- Clinical trial uncertainty — Forward-looking statements note inherent risks in clinical drug development and comparability issues with other sponsors' results [sec · filed 2026-06-15].
- Thin equity cushion — Shareholders' equity of $44.5M against $116.8M cash indicates accumulated deficits and limited buffer beyond cash runway [sec].
What to watch
- NMRA-898 Phase 1 data expected in second half of 2026 [sec · filed 2026-06-15].
- NMRA-511 clinical data in Alzheimer's agitation expected in Q4 2026 [news · published 2026-08-14].
- NMRA-215 IND submission in Q4 2026 and Phase 1 initiation by end of 2026 [news · published 2026-08-14].
- Cash runway into Q3 2027; any changes in spending or financing will affect development timeline [sec · filed 2026-06-15].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run Neumora Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Neumora Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.81 · 0% dilution
Lead: Phase 3
7 candidates
No upcoming catalysts tracked
0 buys · 11 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 28, 2026- % of float
- 4.3%
- Days to cover
- 3.8
- Shares short
- 4,469,003
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NMRA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Neumora Therapeutics, Inc.?
Neumora Therapeutics (NMRA) is a clinical-stage biopharmaceutical company developing a pipeline of novel CNS and metabolic disease programs, with a focus on precision neuroscience and mechanisms such as NLRP3 inhibition, M4 PAM, and V1aR antagonism.
What is Neumora Therapeutics, Inc.'s lead drug candidate?
Neumora Therapeutics, Inc.'s most advanced tracked candidate is navacaprant (Phase 3) for major depressive disorder.
Who is the CEO of Neumora Therapeutics, Inc.?
Dr. Joshua Pinto Ph.D. is the chief executive officer of Neumora Therapeutics, Inc. (NMRA).
Where is Neumora Therapeutics, Inc. headquartered?
Neumora Therapeutics, Inc. (NMRA) is headquartered in Watertown, MA, United States.
What therapeutic areas does Neumora Therapeutics, Inc. focus on?
Neumora Therapeutics, Inc. develops therapies across Neurology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.